KAREN WHITEHEAD: Open Payments
NPI 1295037299 · WASHINGTON, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$471 in 18 payments from 10 companies in 2025. Trend: 2023 $1,074 · 2024 $349 · 2025 $471
Food & beverage: $451Long term medical supply or device loan: $20
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 3 | $167 |
| Otsuka America Pharmaceutical, Inc. | 3 | $73 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Abbott Laboratories | 2 | $44 |
| Dexcom, Inc. | 2 | $37 |
| ABBVIE INC. | 1 | $29 |
| Indivior Inc. | 1 | $23 |
| Neurocrine BioSciences, Inc. | 1 | $19 |
| PFIZER INC. | 1 | $17 |
| Novo Nordisk Inc | 1 | $15 |
Products named: REPATHA, REXULTI, Dexcom G6 Transmitter, UZEDY, VRAYLAR, OTEZLA, FREESTYLE LIBRE 2, SUBLOCADE.
Industry payments across NC — which companies pay providers there.
